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Objectives: To estimate chlamydia prevalence among 16-29 year olds attending general 
practice.  
Design: Cross-sectional survey conducted May 2010 to December 2012.  
Setting: 134 general practice clinics taking part in a cluster randomised trial in 54 
rural/regional towns in 4 Australian States and 9 metropolitan clinics. 
Participants: 4284 sexually experienced men and women aged 16 to 29 years (response 
rate 70%).  
Methods: Consecutive patients were recruited and completed a questionnaire and tested for 
chlamydia.  
Outcome: Chlamydia prevalence in general practice. 
Results: 197/4284 tested positive for chlamydia (4.60%;95%Confidence 
Interval[CI]:3.85,5.34%). Prevalence was similar in men (5.17%;95%CI:3.92,6.43%[65/1257]) 
and women (4.36%;95%CI:3.54,5.18%[132/3027];p=0.25) and highest in those reporting 
genital symptoms or a partner with chlamydia – 17.02% in men (95%CI:2.85,31.20%[8/47]); 
9.47% in women (95%CI:5.09,13.85%[16/169]). Nearly three–quarters of cases (73.45% 
[130/177]) were diagnosed in asymptomatic patients attending for non–sexual health reasons 
(83.75% of patients). Prevalence was slightly higher in rural 
(4.81%;95%CI:4.04,5.57[179/3724]) than metropolitan participants 
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(3.10%;95%CI:1.46,4.74%[17/548];p=0.08). In multivariable analysis, increasing partner 
numbers (3+ partners:odds ratio[OR]=5.11;95%CI:2.35,11.08), past chlamydia diagnosis 
(OR=4.35;95%CI:1.52,12.41), and inconsistent condom use (OR=2.90;95%CI:1.31,6.40) 
were significantly associated with chlamydia in men. In women, increasing partner numbers 
(2 partners:OR=2.59;95%CI:1.59,4.23; 3+ partners: OR=3.58;95%CI:2.26,5.68), past 
chlamydia diagnosis (OR=3.13;95%CI:1.62,6.06) and being aged 25 to 29 years 
(OR=0.23;95%CI:0.12,0.44) were associated with chlamydia. 
Conclusions: Chlamydia prevalence is similar in women and men attending general practice. 
Testing only those with genital symptoms or partner with chlamydia would have missed over 
73% of cases. Most men and women are amenable to being tested and treated in general 
practice, even in rural areas.  
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Introduction 
Chlamydia is the most common bacterial sexually transmissible infection (STI) in Australia 
and notifications have nearly quadrupled in the last decade, with over 80,000 cases 
diagnosed in 2012 (1). In women, chlamydia can cause pelvic inflammatory disease (PID) 
and lead to serious health consequences such as ectopic pregnancy and tubal infertility (2-5). 
In men, untreated infection can develop into epididymo-orchitis (6) and in both men and 
women, chlamydia can increase the risk of HIV transmission (7). 
 
Given that over 80% of all chlamydia infections are asymptomatic (8), and testing rates are 
less than 10% in young Australian adults (9), notification data greatly underestimate the 
prevalence. A recent meta-analysis estimating chlamydia prevalence in different settings in 
Australia found that prevalence among young adults ranged from 4–5% in general practice 
and 6–10% in sexual health or family planning clinics (10). However, there were few data 
available for men.  
 
In 2008, the Department of Health and Ageing funded a trial to investigate whether annual 
chlamydia testing for 16–29 year olds in general practice (GP) clinics can reduce chlamydia 
prevalence (11). The Australian Chlamydia Control Effectiveness Pilot (ACCEPt) trial was 
initiated in 2010. We report on the findings of the baseline prevalence survey, the largest 
survey to estimate chlamydia prevalence in general practice in Australia conducted to date.  
Methods 
Study design 
The cross-sectional survey measured chlamydia prevalence among sexually experienced 
patients attending GP clinics as the baseline assessment for ACCEPt. All 134 GP clinics and 
Aboriginal medical services in 54 towns (clusters) in rural and regional Victoria (18 towns), 
New South Wales (21 towns), Queensland (11 towns) and South Australia (four towns) have 
been enrolled. To be eligible for inclusion, the town had to have a minimum of 500 people 
between 16-29 years in the 2006 census, be 150 kilometres away from an Australian capital 
city and have fewer than seven clinics in the town. Towns were excluded if a military base, 
university or mine was nearby or if it was a tourist town. A list of towns from each state was 
made and towns were selected in no particular order until the required sample size was 
obtained. ACCEPt is based in rural/regional towns to reduce the possibility that patients will 
attend both participating and non-participating clinics which is more likely to happen in a large 
city. However, we included another nine metropolitan GP clinics to collect some data for 
urban areas. Over 85% of clinics approached agreed to participate. 
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Recruitment of participants  
Participants were recruited when they attended the clinic for a consultation. A University of 
Melbourne employed research assistant was based in each clinic for up to 6 weeks and 
invited consecutive patients to participate as they arrived. Men and women were eligible if 
they were between 16–29 years (17–29 years in Queensland and South Australia), and had 
ever had vaginal and/or anal sex. Participants gave written consent, completed a 
questionnaire on a hand-held computer and provided a self-collected urine specimen or 
vaginal swab for chlamydia testing. The questionnaire included items about demographic 
characteristics, sexual behaviour, reasons for attending and genital symptoms. Sexual 
behaviour questions included number of partners in the last 12 months, concurrency (2 or 
more overlapping partnerships), duration of most recent partnership and condom use 
(inconsistent or consistent use with most recent partner). The survey was conducted between 
May 2010 and December 2012. 
Testing and management of positive cases 
Chlamydia tests were conducted by the clinics’ usual pathology providers. All pathology 
laboratories used nucleic acid amplification tests to detect Chlamydia trachomatis. Positive 
chlamydia diagnoses were managed by the clinic; clinics were supplied with one gram doses 
of azithromycin for positive patients. Partner notification resources and advice were provided 
to all clinics. 
Sample size 
Assuming an intracluster correlation coefficient (ICC) of 0.009 (12) and a cluster size of 80, a 
total sample size of 4000 would provide precision of ±0.8% for a prevalence of 4%. This will 
provide a precision of ±1% in women and ±1.4% in men assuming 70% of clinic attenders will 
be women. Between 60 and 100 participants were enrolled from each town or metropolitan 
clinic.  
Analysis of results 
We estimated the prevalence in clinic attenders as the proportion of positive results among 
those tested. The chlamydia prevalence and 95% confidence intervals (95%CI) were 
calculated. Factors associated with chlamydia were investigated; odds ratios (OR) and 
95%CIs were calculated using a random effects logistic regression model. Demographic 
characteristics such as age, education and geographical location, sexual behaviour variables 
such as number of partners in last 12 months, duration of partnership and condom use and 
health care utilisation variables such as previous chlamydia testing or reason for GP 
attendance were examined. Some variables were highly correlated with others and the 
likelihood ratio test was used to determine which variable to include in the multivariable 
model. Covariates which had weak statistical evidence of an association with prevalence 
(p≥0.1) in the univariable analyses were excluded from the multivariable model. All analyses 
accounted for potential intracluster correlation within the town or metropolitan clinic; we used 
the survey commands for the prevalence estimates and panel commands for the logistic 
regression. All analysis was conducted using Stata 12.0
TM
 (College Station, Texas). 
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Ethical approval was obtained from the Royal Australian College of General Practitioners, the 
Aboriginal Health & Medical Research Council and the University of Melbourne Human 
Research Ethics Committees.  
Results 
Response rates 
A total of 4284 patients participated in the prevalence survey: 3027 (70.66%) women and 
1257 (29.34%) men. The response rate was 69.67%; 71.52% for women and 65.65% for men 
(p<0.01).  
Demographic and sexual behaviour profile 
One quarter (24.28% [1040/4284]) of participants was aged 16–19 years, 5.97% (240/4017) 
reported Aboriginal and/or Torres Strait Islander background and 93.75% (3793/4046) were 
born in Australia. Most participants (87.17% [3724/4272]) were recruited from rural/regional 
clinics. A total of 699/3924 (17.81%) reported 3+ partners in the last 12 months and 43/1123 
(3.83%) men and 262/2813 (9.31%) women reported having ever had same sex contact. 
Health care utilisation and reasons for attending 
Women were more likely to have attended the same clinic in the last 12 months (84.47% 
[2371/2807] versus 77.10% [818/1061], p<0.01) and more likely to be attending for a sexual 
health related reason (19.99% [552/2761] versus 7.08% [80/1129], p<0.01) (Table 1). Twice 
as many women (48.02% [1215/2530]) as men (24.02% [262/1091]) could recall ever being 
tested for chlamydia (p<0.01). About 86.94% [3042/3499] of men and women in rural areas 
were attending a clinic within their local postcode compared with 57.76% [309/535] in 
metropolitan areas (p<0.01).  
Prevalence of chlamydia 
There were 197 cases of chlamydia, with an overall prevalence of 4.60% (95%CI:3.85, 5.34). 
The ICC for chlamydia prevalence within clusters or metropolitan clinics was 0.004. 
Prevalence was 5.83% (95%CI:2.91, 8.76% [14/240]) among those reporting Aboriginal 
and/or Torres Strait Islander background and similar between men (5.17%; 95%CI:3.92, 
6.43% [65/1257]) and women (4.36%; 95%CI:3.54, 5.18% [132/3027]; p=0.25). Prevalence 
was slightly higher in rural participants (4.81%; 95%CI:4.04, 5.57% [179/3724]) than 
metropolitan participants (3.10%; 95%CI:1.46, 4.74% [17/548]; p=0.08). Prevalence was 
highest among 16–19 year old women (7.95%; 95%CI:5.87, 10.03%), but among men, 
prevalence was highest in 20–24 year olds (6.64%; 95%CI:4.32, 8.96%) (Table 2). Overall, 
prevalence was highest among those presenting with genital symptoms or contact with a 
partner with an STI – 17.02% in men (95%CI:2.85, 31.20%) and 9.47% in women 
(95%CI:5.09, 13.85%). However, 73.45% (130/177) of infections were in participants 
presenting for a non–sexual health related consultation with a prevalence of 3.99% 
(95%CI:3.18, 4.80%). 
Factors associated with chlamydia 
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In multivariable analyses for men, the odds of chlamydia were significantly increased for an 
increasing number of partners in the last 12 months (3+ partners: OR=5.11; 95%CI:2.35, 
11.08), previous chlamydia diagnosis in the last 12 months (OR=4.35; 95%CI:1.52, 12.41) 
and inconsistent condom use with the most recent partner (OR=2.90; 95%CI:1.31, 6.40). 
Concurrency and duration of partnerships were highly correlated with number of partners; 
number of partners had the strongest association with chlamydia and was included in the 
model. 
In multivariable analyses for women, the odds of chlamydia were significantly increased for an 
increasing number of partners (2 partners: OR=2.59, 95%CI:1.59, 4.23; 3+ partners per year: 
OR=3.58; 95%CI:2.26, 5.68) and previous chlamydia diagnosis (OR=3.13; 95%CI:1.62, 6.06). 
The odds were decreased for 25-29 year olds relative to 16-19 year olds (OR=0.23; 
95%CI:0.12, 0.44). Education was highly correlated with age; age had the strongest 
association with chlamydia and was included in the model. As in men, number of partners 
was highly correlated with duration of partnership and concurrency but had a stronger 
association and was included in the model. 
Discussion 
We have conducted Australia’s largest survey of chlamydia prevalence to date and found that 
4.60% of sexually experienced 16–29 year old men and women attending GP clinics have 
chlamydia. Prevalence was similar between the sexes, highlighting the importance of 
including men in any chlamydia control strategies. Notably, 74% of infections were diagnosed 
among patients attending for a non–sexual health related reason. If only symptomatic patients 
were tested, then three–quarters of chlamydia cases would be missed; this emphasises the 
need to offer testing to all young people. In conjunction with our high participation rate, over 
80% of rural participants were attending their local GP, providing evidence that young adults 
living in rural Australia will agree to be tested at their local clinic if asked.   
The strengths of this study are: the large sample size; high participation of 70%; and the large 
number of men tested. However, there are also limitations. Firstly, selection bias cannot be 
ruled out despite the high response rate, as the sexual practices of non-responders and 
responders could not be compared. Secondly, participants were recruited from general 
practice and not from the general population. Conducting a population-based survey of 
chlamydia prevalence is extremely challenging, partly due to the choice of sampling frame 
and the generally low response rates (12). However, given our high response rate of 70% and 
the fact that 64% of men and 86% of women in this age group attend a GP for their own 
health each year (9), recruiting from every general practice in each town does provide a 
quasi-population approach to estimating prevalence. Thirdly, as it was a largely rural sample, 
the demographics of the study population differed from the most recent Australian census 
data (13); participants were more likely to be Australian born (94% versus 73%, p<0.01) and 
more likely to be Aboriginal and/or Torres Strait Islander (6% versus 3%, p<0.01). Fourthly, 
we did investigate several different risk factors for their association with chlamydia, raising 
issues of statistical multiplicity. However, these variables have been previously found to be 
associated with chlamydia and were pre-specified in our analysis plan. Finally, only 30% of 
the sample was male, but this reflects the attendance pattern at our clinics; Medicare GP 
consultation data show twice as many consultations for women annually than men in this age 
group (14).  
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Our estimated prevalence of 4.36% among young women is consistent with findings from 
Walker and colleagues among a similar sample of women (15). However, our prevalence of 
5.17% among men is higher than the 3.7% reported by Hince and colleagues among a similar 
sample of urban men (16). It is possible that prevalence is higher in rural men than 
metropolitan men, due to reduced access to health care (17). Our study does provide some 
weak evidence of a higher prevalence in rural areas versus metropolitan areas (4.81% versus 
3.10%, p=0.08), which was not explained by any differences in sexual behaviour as 
metropolitan participants reported a greater number of partners in the last 12 months (p<0.01) 
and were more likely to report a concurrent partnership (p<0.01). 
In women, prevalence was highest among 16–19 year olds (7.95%) and lowest among 25–29 
year olds (1.23%). Conversely, in men, the highest prevalence was in 20–24 year olds 
(6.64%), and was still elevated in the 25–29 year olds (3.70%). This probably reflects sexual 
mixing as men are often up to five years older than their female partners (18). Measures of 
risky sexual behaviours such as multiple partners in the last 12 months, concurrency and a 
partnership of short duration were all strongly associated with chlamydia, but multivariable 
modelling showed that number of partners was the most important variable associated with 
chlamydia. It can be difficult designing the content of a sexual behaviour survey (19), but we 
have shown that a question about number of partners should be included.   
The majority of testing and diagnosis of chlamydia takes place in general practice in Australia. 
When asked, GPs say that testing should be their responsibility (20), yet testing rates among 
young adults remain low, particularly among young men (3.7% versus 12.5% in women) (9). 
Studies have suggested that young people, particularly those in rural areas, do not wish to 
discuss sexual health issues with GPs because of privacy concerns and will not seek testing 
(17, 21). However, our study suggests that initiating a discussion about testing with a patient 
may often be sufficient to overcome these concerns, as 70% of eligible participants accepted 
a chlamydia test when offered.  
Conclusion 
Prevalence of chlamydia is high in both men and women attending GP clinics, particularly in 
rural areas. Current practices of testing mainly those with symptoms or STI contact would 
have missed nearly 75% of these infections. However, young men and women were 
amenable to being tested and treated in general practice when asked, which suggests that 
offering a test in the general practice setting would reach the majority of young adults.   
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Table 1: Healthcare access patterns and reasons for attending 
Variable Proportion (%) 
Men Women P value Rural Metro P value 
Seen a doctor in the last 
12 months 
Yes 83.45% [943/1130] 91.01% [2561/2814] <0.01 88.94% [3032/3409] 88.07% [465/528] 0.55 
Attended this clinic 
before 
 
Never 16.49% [175/1061]  10.79% [303/2807] <0.01 11.42% [381/3336] 18.48% [97/525] <0.01 
Yes  <12 months ago 77.10% [818/1061] 84.47% [2371/2807]  83.03% [2770/3336] 78.48% [412/525]  
Yes  12+ months ago 6.41% [68/1061] 4.74% [133/2807]  5.55% [185/3336] 3.05% [16/525]  
Reason for attending1 STI related reasons – 
contact/symptoms 
4.16% [47/1129] 6.12% [169/2761] <0.01 4.74% [159/3357] 10.84% [57/526] <0.01 
Other sexual health 
related reasons 
2.92% [33/1129] 13.87% [383/2761]  10.78% [362/3357] 9.52% [52/526]  
Non-sexual health 92.91% 
[1049/1129] 
80.01% [2209/2761]  84.48% [2836/3357] 79.28% [417/526]  
Tested previously for 
chlamydia 
Yes  <12 months ago 13.20% [144/1091] 24.82% [628/2530] <0.01 20.55% [642/3124] 26.53% [130/490] <0.01 
Yes  12+ months ago 10.82% [118/1091] 23.20% [587/2530]  20.29% [634/3124] 14.29% [70/490]  
No 75.99% [829/1091] 51.98% [1315/2530]  59.15% [1848/3124] 59.18% [290/490]  
Willing to have another 
chlamydia test in 12 
months 
Yes 80.00% [728/910] 87.93% [2178/2477] <0.01 85.06% [2500/2939] 90.74% [402/443] <0.01 
No 20.00% [182/910] 12.07% [299/2477]  14.94% [439/2939] 9.26% [41/443]  
Distance to clinic for 
postcodes 
Within same or neighbouring 
postcode 
81.62% [959/1175] 83.68% [2399/2867] 0.11 86.94% [3042/3499] 57.76% [309/535] <0.01 
1. Multiple answers given for reasons attending – STI related reasons given preference over contraception/pap smear, and over other SH-related reasons 
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Table 2: Chlamydia prevalence
1
 in GP clinic attenders and odds ratios for factors associated with chlamydia by gender
2 
Variable  Men Women 
  Prevalence (%)  
(95%CI) 
Number Unadjusted  
Odds Ratio 
Adjusted  
Odds Ratio 
P-value Prevalence (%)  
(95%CI) 
Number Unadjusted  
Odds Ratio 
Adjusted  
Odds Ratio 
P-value 
            
Age 16-19 4.70% (1.92%, 7.47%) 14/298 Ref.3 Ref.  7.95% (5.87%, 10.03%) 59/742 Ref. Ref.  
20-24 6.64% (4.32%, 8.96%) 35/527 1.44 (0.76, 2.74) 1.04 (0.50, 2.21) 0.90 5.15% (3.69%, 6.61%) 59/1145 0.63 (0.43, 0.92) 0.81 (0.54, 1.23) 0.32 
25-29 3.70% (2.13%, 5.28%) 16/432 0.78 (0.37, 1.63) 0.74 (0.30, 1.79) 0.50 1.23% (0.60%, 1.85%) 14/1140 0.14 (0.08, 0.26) 0.23 (0.12, 0.44) <0.01 
            
State VIC 5.30% (3.55%, 7.05%) 31/585 Ref.   4.21% (2.85%, 5.57%) 56/1331 Ref.   
NSW 5.37% (3.03%, 7.72%) 23/428 1.01 (0.58, 1.77)   4.50% (3.13%, 5.87%) 47/1044 1.05 (0.69, 1.62)   
QLD 5.08% (1.92%, 8.25%) 9/177 0.96 (0.45, 2.05)   5.15% (3.74%, 6.55%) 25/505 1.22 (0.73, 2.04)   
SA 2.99% (0.00%, 6.71%) 2/67 0.55 (0.13, 2.35)   2.0% (0.27%, 3.81%) 3/147 0.46 (0.14, 1.56)   
            
Location Rural 5.53% (4.21%, 6.86%) 59/1066 2.12 (0.84, 5.36)   4.51% (3.67%, 5.36%) 120/2658 1.34 (0.70, 2.54)   
Metropolitan 2.69% (0.57%, 4.80%) 5/186 Ref.   3.31% (0.84%, 5.79%) 12/362 Ref.   
            
Aboriginal and/or 
Torres Strait 
Islander 
Yes 4.69% (0.00%, 9.40%) 3/64 Ref.   6.25% (2.79%, 9.71%) 11/176 Ref.   
No 5.08% (3.77%, 6.39%) 56/1103 1.09 (0.33, 3.57)   4.23% (3.39%, 5.06%) 113/2674 0.67 (0.35, 1.28)   
            
Country of birth Australia 5.27% (3.99%, 6.55%) 58/1100 Ref.   4.49% (3.66%, 5.33%) 121/2693 Ref.   
Other 1.28% (0.00%, 3.94%) 1/78 0.23 (0.03, 1.71)   2.86% (0.00%, 5.80%) 5/175 0.64 (0.26, 1.61)   
            
Level of 
Education 
High school 5.36% (3.86%, 6.86%) 47/877 Ref.   5.06% (4.01%, 6.11%) 99/1956 Ref.   
Trade/ 
Diploma 
4.10% (1.05%, 7.15%) 8/195 0.76 (0.35, 1.63) 
 
  3.81% (2.03%, 5.58%) 19/499 0.73 (0.44, 1.21)   
Tertiary 3.03% (0.02%, 6.04%) 3/99 0.55 (0.17, 1.81)   1.72% (0.41%, 3.02%) 7/408 0.33 (0.15, 0.72)   
            
Number of 
partners in the 
last 12 months4 
0/1 1.97% (0.85%, 3.10%) 12/609 Ref. Ref.  2.39% (1.68%, 3.10%) 48/2007 Ref. Ref.  
2 5.61% (1.90%, 9.33%) 11/196 3.00 (1.30, 6.94) 2.43 (0.94, 6.27) 0.07 7.51% (4.92%, 10.09%) 31/413 3.35 (2.10, 5.35) 2.59 (1.59, 4.23) <0.01 
3+ 10.93% (6.90%, 14.96%) 34/311 6.28 (3.16, 12.48) 5.11 (2.35, 11.08) <0.01 10.82% (7.22%, 14.43%) 42/388 5.02 (3.25, 7.74) 3.58 (2.26, 5.68) <0.01 
            
Same-sex partner 
ever 
No  4.81% (3.47%, 6.16%) 52/1080 Ref.   4.39% (3.54%, 5.24%) 112/2551 Ref.   
Yes 6.98% (0.00%, 13.98%) 3/43 1.48 (0.44, 4.95)   3.81% (0.90%, 6.73%) 10/262 0.86 (0.45, 1.67)   
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Variable  Men Women 
  Prevalence (%)  
(95%CI) 
Number Unadjusted  
Odds Ratio 
Adjusted  
Odds Ratio 
P-value Prevalence (%)  
(95%CI) 
Number Unadjusted  
Odds Ratio 
Adjusted  
Odds Ratio 
P-value 
            
Sexual health 
related consult 
Symptoms 
or contact5 
17.02% (2.85%, 31.20%) 8/47 4.92 (2.04, 11.84) 2.33 (0.86, 6.37) 0.10 9.47% (5.09%, 13.85%) 16/169 2.64 (1.51, 4.64) 1.68 (0.91, 3.11) 0.10 
Other sexual 
health 
reasons6 
9.09% (0.00%, 18.48%) 3/33 2.22 (0.65, 7.65) 1.78 (0.48, 6.67) 0.39 5.22% (2.94%, 7.51%) 20/383 1.39 (0.84, 2.29) 1.19 (0.70, 2.01) 0.52 
No 4.29% (2.98%, 5.60%) 45/1049 Ref. Ref.  3.85% (2.96%, 4.74%) 85/2209 Ref. Ref.  
            
Previous 
chlamydia test 
No 5.07% (3.58%, 6.55%) 42/829 Ref.   4.79% (3.77%, 5.82%) 63/1315 Ref.   
Yes <12 
months 
6.25% (2.06%, 10.44%) 9/144 1.26 (0.60, 2.66)   4.30% (2.30%, 6.30%) 27/628 0.90 (0.56, 1.43)   
Yes 12+ 
months 
5.08% (0.70%, 9.47%) 6/118 1.00 (0.42, 2.42)   3.75% (2.45%, 5.05%) 22/587 0.77 (0.47, 1.27)   
            
Previous 
chlamydia 
diagnosis 
No 4.55% (3.37%, 5.74%) 54/1186 Ref. Ref.  4.07% (3.28%, 4.86%) 113/2776 Ref. Ref.  
Yes <12 
months 
25.81% (8.33%, 43.28%) 8/31 7.35 (3.06, 17.61) 4.35 (1.52, 12.41) <0.01 18.92% (8.22%, 29.62%) 14/74 5.43 (2.93, 10.07) 3.13 (1.62, 6.06) <0.01 
Yes 12+ 
months 
5.13% (0.00%, 11.82%) 2/39 1.13 (0.27, 4.84) 0.51 (0.06, 3.96) 0.52 2.35% (0.01%, 4.69%) 4/170 0.57 (0.21, 1.56) 0.62 (0.22, 1.74) 0.37 
            
Concurrency7 No 3.80% (2.59%, 5.01%) 35/921 Ref.   3.71% (2.91%, 4.50%) 93/2510 Ref.   
Yes 10.09% (5.77%, 14.40%) 23/228 2.84 (1.64, 4.91)   9.65% (6.22%, 13.08%) 33/342 2.80 (1.84, 4.25)   
            
Condom use with 
the most recent 
partner8 
Consistent 2.14% (0.58%, 3.71%) 8/373 Ref. Ref.  4.39% (2.90%, 5.88%) 35/797 Ref.   
Inconsistent 6.85% (5.03%, 8.68%) 47/686 3.36 (1.57, 7.18) 2.90 (1.31, 6.40) <0.01 4.54% (3.46%, 5.62%) 87/1916 1.03 (0.69, 1.55)   
            
Duration of most 
recent partnership 
5 years or 
more 
1.26% (0.00%, 3.04%) 2/159 Ref.   0.95% (0.19%, 1.71%) 6/632 Ref.   
3-4 years 3.10% (0.22%, 5.98%) 4/129 2.46 (0.44, 13.76)   1.28% (0.17%, 2.38%) 5/392 1.36 (0.41, 4.48)   
1-2 years 2.29% (0.02%, 4.54%) 4/175 1.86 (0.33, 10.36)   4.76% (2.63%, 6.89%) 23/483 5.25 (2.11, 13.01)   
6-12 months 9.84% (4.59%, 15.08%) 12/122 8.78 (1.91, 40.34)   5.46% (2.82%, 8.10%) 13/238 6.07 (2.28, 16.19)   
Less than 6 
months 
7.73% (4.72%, 10.75%) 28/362 6.65 (1.56, 28.37)   9.24% (7.00%, 11.49%) 66/714 10.74 (4.61, 25.00)   
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Variable  Men Women 
  Prevalence (%)  
(95%CI) 
Number Unadjusted  
Odds Ratio 
Adjusted  
Odds Ratio 
P-value Prevalence (%)  
(95%CI) 
Number Unadjusted  
Odds Ratio 
Adjusted  
Odds Ratio 
P-value 
            
Antibiotic use in 
the last three 
months 
No 5.24% (3.78%, 6.70%) 44/839 Ref.   4.58% (3.55%, 5.62%) 96/2095 Ref.   
Yes 4.46% (1.25%, 7.68%) 10/224 0.84 (0.42, 1.71)   3.69% (2.30%, 5.07%) 23/624 0.79 (0.49, 1.26)   
            
Visit any GP in 
the last 12 
months 
No 4.81% (1.97%, 7.65%) 9/187 Ref.   5.14% (2.46%, 7.81%) 13/253 Ref.   
Yes 5.09% (3.52%, 6.66%) 48/943 1.07 (0.51, 2.22)   4.30% (3.42%, 5.17%) 110/2561 0.82 (0.46, 1.49)   
            
Travelled to clinic 
within same or 
contiguous 
postcode 
No 6.94% (2.67%, 11.22%) 15/216 Ref.   3.63% (1.70, 5.56%) 17/468 Ref.   
Yes 4.59% (3.29%, 5.89%) 44/959 0.64 (0.34, 1.20)   4.54% (3.66, 5.42%) 109/2399 1.24 (0.73, 2.10)   
1. Proportion positive among those tested at participating clinics; 2. Results have accounted for clustering; 3. Ref. = reference category; 4. Opposite sex partners only; 5. Symptoms or STI 
contact; 6. Contraception, Pap smear, new partner/STI check; 7. Overlap in sexual partnerships; 8. Consistent use is defined as always or mostly used condoms. Inconsistent use is never, 
infrequently, or sometimes used condoms 
